Publications
Key Publications
(EX937 = URB937)
Our Programs
EX937
EX937 is an innovative small molecule being developed for the treatment of refractory chronic cough, a condition that affects approximately 10% of the global population. Leveraging a novel and differentiated approach, by peripherally inhibiting the FAAH enzyme, EX937 has demonstrated marked efficacy and favorable safety in preclinical models.
EX14280 and EX14663
These globally active FAAH inhibitors leverage a chemical scaffold similar to EX937 to achieve body-wide enhancement of anandamide-mediated signaling. Substantial preclinical and clinical data with these and other FAAH inhibitors indicate potential usefulness in the treatment of Social Anxiety Disorder and Autism Spectrum Disorder.